Tezepelumab COPD Exacerbation Study

Clinical Trial ID: NCT04039113


A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of tezepelumab in adults with moderate to very severe chronic obstructive pulmonary disease (COPD) receiving triple inhaled maintenance therapy, and having had 2 or more documented COPD exacerbations in the 12 months prior to Visit 1. Approximately, 282 subjects will be randomized globally. Subjects will be stratified by region and prior number of exacerbations (2 vs. 3 or more). Subjects will receive tezepelumab, or placebo, administered via subcutaneous injection at the study site, over a 52 week treatment period. The study also includes a post-treatment follow-up period of 12 weeks.


Inclusion Criteria: 1. History of moderate to very severe physician-diagnosed COPD for at least 12 months prior to enrolment with a post-bronchodilator FEV1/FVC<0.70 and a post-bronchodilator FEV1 ≥20% and ≤80% of predicted normal value. 2. History of at least 2 documented moderate to severe COPD exacerbations within 2 to 52 weeks prior to enrollment. 3. CAT score of ≥15 at enrollment and on day of randomization. 4. Documented treatment with triple therapy for COPD (medium or high dose ICS/LABA/LAMA) throughout the year prior to enrollment. The dose of ICS should be stable for 3 months prior to enrollment. 5. Chest x-ray, CT scan or MRI scan of the chest/lungs must not show suspected lung pathology that prevents the patient's ability to complete the study. Exclusion Criteria: 1. Clinically important pulmonary disease other than COPD, as judged by the Investigator (including current or historic asthma diagnosis). 2. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious (including risk factors for pneumonia), endocrine, metabolic, hematological, psychiatric, or major physical impairment that is not stable. 3. Major surgery within 8 weeks before enrollment. 4. History of clinically significant infection requiring antibiotics or antiviral medication within 14 days before enrollment. 5. Pregnant or breastfeeding.

  • Start Date


  • Last Updated


  • Sponsor


  • Condition Name

    Chronic Obstructive Pulmonary Disease (COPD)

Learn about this trial.

Check the eligibility requirements, study details, and more.

Related Trials

Different trials target different symptoms, condition types, and patients. Learn more about other emergeing treatments being investigated now.